Immunwork reports 120-hour half-life for TE-8105 in Phase 1/2a GLP-1 trial
First-in-human data position the Taiwanese biotech alongside Pfizer in the push for less-than-weekly GLP-1 dosing, with Phase 2b trials in Australia and Taiwan planned for Q4 2026.